Preclinical News and Research

RSS

Novel regulators in digestive tract disease progression and treatment

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive tract diseases, positioning these molecules as potential biomarkers for diagnosis, prognosis, and targeted therapies. The comprehensive review explores the biogenesis, classification, and biological functions of tsRNAs, shedding light on their influence over cellular processes such as translation regulation, epigenetic modification, and protein interactions.

11 Mar 2025

Stress and obesity found to fuel early pancreatic cancer growth

A new study led by UCLA investigators suggests that chronic stress and an unhealthy diet may work together to fuel the early development of pancreatic cancer, shedding light on how lifestyle factors contribute to one of the deadliest malignancies.

10 Mar 2025

Scientists discover key molecular switch for blood stem cell regeneration

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell Medicine investigators.

10 Mar 2025

Can microbiome discoveries finally become treatments? Scientists show the way

Researchers propose a novel iterative strategy combining big data and experimental models to move microbiome research from theory to clinical applications. The study highlights the need to bridge the gap between correlation and causation to develop effective microbiome-based therapies.

9 Mar 2025

Vanderbilt researchers aim to use AI to develop antibody therapies for any target

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

8 Mar 2025

Eradivir begins Phase 2 challenge study for antiviral therapeutic EV25

Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will provide safety and efficacy data gathered from otherwise healthy participants infected with influenza then later treated with EV25.

7 Mar 2025

Insilico Medicine's AI-driven drug Rentosertib receives official generic name

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, recently announced that its breakthrough drug candidate for idiopathic pulmonary fibrosis (IPF) – Rentosertib (formerly known as ISM001-055) – has been granted an official generic name by the United States Adopted Names (USAN) Council.

7 Mar 2025

Phase 1 trial examines safety and feasibility of stem cell treatment for Parkinson's

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to replace dopamine cells in the brain damaged by the disease.

6 Mar 2025

Chronic cocaine use increases impulsivity

Findings indicate chronic cocaine use alters brain circuits, increasing impulsivity in low-impulsive rats, contradicting previous assumptions about addiction.

5 Mar 2025

Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections

Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the selection of its first clinical candidate in the ABX-01 program.

4 Mar 2025

Novel strategy targets beta cell dysfunction in type 2 diabetes

Researchers from the Icahn School of Medicine at Mount Sinai in New York have discovered a novel approach to protecting insulin-producing beta cells from the damaging effects of glucolipotoxicity-a harmful condition linked to the progression of type 2 diabetes (T2D).

4 Mar 2025

Stem cell therapy for cornea injuries demonstrates remarkable results in clinical trial

An expanded clinical trial that tested a groundbreaking, experimental stem cell treatment for blinding cornea injuries found the treatment was feasible and safe in 14 patients who were treated and followed for 18 months, and there was a high proportion of complete or partial success.

4 Mar 2025

Alpha particle therapy offers new hope for neuroendocrine tumors

In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumors (NETs), a rare but increasingly prevalent form of cancer.

4 Mar 2025

Non-invasive 40Hz gamma stimulation could help fight Alzheimer’s

A decade after scientists in The Picower Institute for Learning and Memory at MIT first began testing whether sensory stimulation of the brain's 40Hz "gamma" frequency rhythms could treat Alzheimer's disease in mice, a growing evidence base supporting the idea that it can improve brain health-in humans as well as animals-has emerged from the work of labs all over the world.

3 Mar 2025

Pioneering the world’s first CRISPR medicine for sickle cell disease

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters was with a 24-year-old patient whose sickle cell disease left them with almost weekly pain episodes.

3 Mar 2025

New three-organ system offers an animal-free alternative for pharmacokinetics research

Innovative organ-on-chip specialist Dynamic42 and ESQlabs, experts in digital life sciences solutions, have successfully developed a three-organ system, in close collaboration with Consumer Health Division of Bayer, and the Placenta Lab at Jena University Hospital.

2 Mar 2025

Researchers uncover how brain tumors reprogram neutrophils to hinder cancer treatment

The lab of Filippo Veglia, Ph.D., at The Wistar Institute has discovered a previously unknown mechanism for how aggressive brain cancers reprogram immune system cells from fighting cancer to enabling further tumor growth.

2 Mar 2025

Ursodeoxycholic acid shows promise in treating drug-induced liver injury

Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary supplements.

28 Feb 2025

European project aims to develop new treatments for rare eye diseases

The Ocular Neurobiology laboratory at the Institute for Neurosciences, a joint center of Miguel Hernández University (UMH) in Elche and the Spanish National Research Council (CSIC), is participating in the European project RESTORE VISION, an ambitious initiative aimed at developing new treatments for rare eye diseases such as aniridia and neurotrophic keratopathy.

28 Feb 2025